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Abstract 
Breast cancer is the second leading cause of cancer mortality in women, and metastatic disease is 
responsible for the majority of deaths. Epithelial cells within a tumor can undergo an epithelial-
mesenchymal transition (EMT), enabling the cells to break free from the primary tumor and 
invade surrounding tissues. Recently, myoferlin (MYOF), a protein involved in cell membrane 
functions, was found to be overexpressed in the breast cancer cell line MDA-MB-231, and 
knocking down MYOF in these cells reduces invasion and reverts the cells to a more epithelial 
phenotype. However, it is unknown why knocking out MYOF leads to the reversal of EMT, and 
whether this change is permanent. Transforming growth factor β1 (TGF-β1) misregulation has 
been shown previously to contribute to the progression of cancer via EMT, and is known to be a 
potent stimulus of the process. To examine if the MYOF knockdown (KD) cells are capable of 
undergoing EMT, they were treated with TGF-β1. After treatment, their morphology converted 
to a more mesenchymal appearance. Therefore, we hypothesized that the knockdown of MYOF 
causes a decrease in autocrine TGF-β1 production, reversing EMT. Using an enzyme linked 
immunosorbent assay (ELISA), TGF-β1 levels were shown to have a 20% decrease in MYOF 
KD cells compared to control cells. Similarly, qRT-PCR of TGF-β1 showed about a 30% 
decrease in the mRNA expression levels in MYOF KD cells. Western blot was used to confirm 
the phenotypical change in TGF-β1 treated MYOF KD cells by comparing levels of specific 
markers present in epithelial and mesenchymal cells. Western blot of vimentin, a common 
mesenchymal marker, increased to a level similar to the MDA-MB-231 control cells after TGF-
β1 treatment; E-cadherin, which is characteristic of epithelial cells, showed a significant decrease 
in expression. These findings confirm the EMT of MYOF KD cells after treatment. Studies on 
the effect of TGF-β1 on cell migration revealed a decrease in directionality, further supporting 
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the occurrence of EMT. These results indicate the importance of TGF-β1 in EMT of breast 
cancer cells, and gaining a better understanding of factors related to EMT can aid in the 
development of better and more specific treatment methods.   
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Chapter 1 Introduction 
Breast cancer is the second leading cause of cancer mortality in women, with metastatic 
rather than localized disease leading to the majority of deaths. In the United States, the 5 year 
survival rate for women diagnosed with breast cancer is 99% for localized disease, 85% for 
regional disease, and 26% for distant disease (“Breast Cancer Facts & Figures | American Cancer 
Society” 2017). Epithelial-mesenchymal transition (EMT) is a process that can contribute to the 
metastasis of cancer cells, involving epithelial cells losing their cell-cell adhesions and gaining 
motility, allowing them to break away from the primary tumor and invade the surrounding tissue, 
infiltrate the blood vessels, and form a secondary tumor at another location in the body. By 
studying what leads to this transition in cancer cells, potential targets for more specialized 
therapeutic methods can be identified. The protein myoferlin (MYOF) was previously discovered 
to be overexpressed in invasive breast cancer lines (Li et al. 2012). After knocking down MYOF 
in the invasive breast cancer cell line MDA-MB-231, the cells exhibited a change to an epithelial 
phenotype, or a mesenchymal-epithelial transition (MET). It was unclear, however, why 
knocking down MYOF led to this MET, and if the change would permanently alter part of the 
mechanism of EMT, preventing it from occurring. In order for EMT to occur, cells must sense a 
stimulus and subsequently undergo a series of biochemical changes leading to the mesenchymal 
phenotype. In this study, we seek to discover what aspect of EMT knockdown of myoferlin is 
altering, the mechanism or the stimulus. We hypothesized that myoferlin depletion leads to a 
reduction in transforming growth factor β1 (TGF-β1) production, resulting in MET. To 
determine if MDA-MB-231 MYOF knockdown (KD) cells were able to undergo EMT, the cells 
were treated with exogenous TGF-β1, a known cause of EMT in many cell types. This resulted 
in a both morphological and phenotypical changes of the MDA-MB-231 MYOF KD cells to 
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become mesenchymal, based on western blot of EMT markers. Autocrine TGF-β1 
concentrations were directly measured using an enzyme linked immunosorbent assay (ELISA), 
along with mRNA expression using qRT-PCR. Further studies on the effect of TGF-β1 treatment 
on migration were also performed, to validate that the phenotypical change altered cell 
behaviors, such as migration and invasion, as well. 
  
Chapter 2 Background 
2.1 Epithelial-Mesenchymal Transition 
Epithelial-mesenchymal transition (EMT) is a process which allows a polarized epithelial 
cell to undergo biochemical changes enabling it to assume a mesenchymal phenotype (Kalluri 
and Weinberg 2009). There are multiple types of EMT, classified based on the biological context 
in which they occur. The first is type 1 EMT, which occurs during embryogenesis and is 
important for normal development. The major examples of EMT in embryogenesis include 
mesoderm, neural crest, and cardiac valve formation (Yang and Weinberg 2008). There are also 
cases during development where EMT is not an irreversible process permanently forming 
mesenchymal cells, but rather that the cells undergo a mesenchymal-epithelial transition (MET) 
reverting to an epithelial state (Davies 1996). Type 2 EMT occurs during tissue regeneration and 
organ fibrosis, as a response to inflammatory injury. The last type of EMT, type 3, is associated 
with cancer progression and metastasis.  
In order for cancer cells to break away from the primary tumor and neighboring cells, 
they must lose their cell-cell adhesions and gain motility, which is believed to occur through a 
type 3 EMT. EMT has been found to be regulated through many controls at the transcriptional, 
post-transcriptional, translational, and post-translational levels (Craene and Berx 2013).  
A variety of transcriptional factors are known to repress E-cadherin and other cell 
junction proteins. Loss of E-cadherin is associated with cancer progression and poor prognosis, 
since it is a cell adhesion molecule and key part of an epithelial state. In many types of 
carcinoma, the tumor loses E-cadherin expression early during development, and thus the cells 
are in a permanent mesenchymal phenotype, or an irreversible EMT (Guilford et al. 1998). This 
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is not necessarily the case, however, since carcinoma cells are believed to activate the EMT 
process to invade and travel to distant organs, after which they revert via a MET and form 
secondary tumors. While the EMT process in embryonic development is well-defined, in 
carcinoma progression it is difficult to understand, since cells can undergo partial EMT to their 
advantage as well. The transcriptional factors Snail, Slug, and Twist have been found to be 
important in the regulation of the process of EMT, both in normal development and cancer 
progression (Hugo et al. 2007). The Snail family, which includes Slug, represses the 
transcription of the adherens junction E-cadherin by binding an element in the E-cadherin 
promoter, which is also the mechanism by which Twist works (Hugo et al. 2007; Martin et al. 
2005). Twist inhibits oncogene and p53-dependent cell death, thus making it an antiapoptotic 
factor, and is also known to trigger EMT (Martin et al. 2005). 
Non-coding RNAs, including microRNAs (miRNAs) have recently been found to be 
important in the regulation of EMT. The miR-200 family is associated with epithelial 
differentiation, and the feedback with an EMT transcription factor controls both EMT and MET 
(Korpal et al. 2008). Additionally, the miR-34 family controls Snail-dependent EMT (Kim et al. 
2011). 
The transforming growth factor-β (TGF-β) family of proteins is known to be important in 
both normal development and cancer progression EMT. Activation of the TGF-β signal pathway 
in later stages of tumor progression was shown to lead to EMT, allowing the cells to spread to 
distant organs (Janda et al. 2002). TGF-β has also been shown to induce Snail and Slug, which 
then would lead to lower expression of E-cadherin.  
The relevance of EMT in clinical settings is often questioned due to the difficulty in 
identifying markers of EMT from clinical samples. This is likely due to the transient nature of 
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EMT changes, along with the fact that it may occur in only a small number of cells at the 
invasive edge of the tumor, which has been supported by clinical data. Most human cancers have 
partial EMT features, and express both markers of epithelial and mesenchymal cells in vivo 
(Craene and Berx 2013). 
Similarly, in a study on pancreatic ductal adenocarcinoma, EMT regulators Snail and 
Twist1 were knocked out to study if this reduces the invasion and metastasis of cancer cells in 
mice. It was found that the cancer cells were still able to proliferate and metastasize. However, 
knocking out Snail and Twist1 did make the tumors more susceptible to the gemcitabine drug, 
where normally EMT is associated with resistance to this drug. Tumor progression was able to 
be suppressed and survival was increased in the knockout mice (Zheng et al. 2015). Another 
study on lung metastasis in breast cancer also found that EMT was not required for metastasis to 
occur, in a mouse model where EMT was suppressed. The study also found that cells that had 
undergone EMT were able to resist chemotherapeutics both in vitro and in vivo (Fischer et al. 
2015). Thus, although not necessary for metastasis, EMT is responsible for drug resistance and 
targeting this process could help lead to improved patient outcomes.  
2.2 Myoferlin 
Myoferlin (MYOF) is a protein of the ferlin family, which are important in cell 
membrane functions such as fusion, repair, and endocytosis. It was shown to be critical for 
endocytosis in epithelial cells, after disrupting the gene resulted in decreased endocytosis 
(Bernatchez et al. 2009). Additionally, a study on pancreatic cancer showed MYOF to be critical 
for the exocytosis of VEGF, as staining for the protein revealed an aggregation at the cell 
membrane after MYOF silencing. They also found significantly lower concentrations of VEGF 
in the conditioned media of the myoferlin silenced cells, but no significant difference in the 
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mRNA expression, leading to the conclusion that myoferlin silencing regulates the exocytosis of 
VEGF. Silencing also led to decreased tumor volume, due to the reduction of blood vessels 
within the tumor (Fahmy et al. 2016).  
MYOF was previously found to be overexpressed in highly invasive breast cancer cell 
lines compared to normal breast tissue. To study how this protein affected the invasive capacity 
of MDA-MB-231 cells, the gene for MYOF was knocked down (Li et al. 2012). After myoferlin 
depletion, the MDA-MB-231 cells appeared to have an epithelial phenotype (Fig 2-1). This 
observation was confirmed by western blot to analyze protein expression, which showed a down-
regulation of the mesenchymal markers fibronectin and vimentin, and corresponding up-
regulation of the epithelial marker E-cadherin. Along with a phenotypical change, the study 
reported a decrease in invasion of the MDA-MB-231 myoferlin knockdown (MYOF KD) cells 
through both matrigel and collagen type I.  
 
Figure 2-1: Effect of Myoferlin Depletion on MDA-MB-231 Cells. Immunofluorescent images showing the 
morphology of MDA-MB-231 wild type (WT), lentiviral control (LTV-ctrl), and myoferlin knockdown (MYOF-
KD). The MYOF-KD cells appear more cobblestone in shape characteristic of epithelial cells, while the WT and 
LTV-ctrl cells have the spindle shape characteristic of mesenchymal cells (Li et al. 2012). 
In addition to the change in phenotype and invasion, MYOF depletion resulted in a 
change in migration patterns to collective migration, with decreased velocity and increased 
directionality of movement (Volakis et al. 2014). Additionally, MYOF depleted cells displayed 
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enhanced cell-substrate adhesion and spreading, more than 2 times greater than control cells 
(Fig. 2-2). In vivo studies in mice found that MYOF KD cells formed smaller, smooth edged 
tumors that did not appear to invade the surrounding tissue, showing that the depletion of 
myoferlin is able to prevent invasion. Furthermore, a similar study on mouse Lewis lung 
carcinoma found that myoferlin knockout in vivo in mice reduced tumor burden and growth (Fig. 
2-3) (Leung et al. 2013). Analysis of the expression of proteins that control cell-matrix 
adhesions, including focal adhesion kinase (FAK) and paxillin (PAX), found cell adhesions in 
MYOF KD cells to be larger and more elongated, with increased localization at the cell 
periphery (Blackstone et al. 2015). These results indicate both by cell structure and activity that 
MDA-MB-231 MYOF KD cells underwent MET. 
 
Figure 2-2: MYOF knockdown MDA-MB-231 cells have enhanced cell-substrate adhesion. A. Relative cell 
adhesion and spreading was calculated and normalized to wild type cells (data not shown). The MYOF knockdown 
cells were found to have cell adhesion and spreading two times greater than the lentiviral control (LTVC) cells. B. 
Cell detachment after addition of trypsin. The release time of MYOF knockdown cells was two times greater than 
LTVC cells (Volakis et al. 2014). 
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Figure 2-3: Study of the growth of tumors in mice after knockdown of myoferlin. A. Lewis lung carcinoma 
cells (LLC) were treated with vehicle, control siRNA, or myoferlin siRNA for 48 and 72 hours, after which proteins 
were isolated to verify knockdown was successful. B. Mice were injected with cells of the various conditions, and 
myoferlin knockdown was found to significantly decrease tumor burden. C. After mice were euthanized, tumors 
were isolated, and proteins were blotted to observe myoferlin expression in the tumors (Leung et al. 2013).  
2.3 Transforming Growth Factor β 
Transforming growth factor β (TGF-β) is a superfamily of growth factors, containing 
over 30 members, including bone morphogenetic proteins (BMPs), growth and differentiation 
factors (GDFs), Activins, and Nodal in addition to TGF-βs, which are important for development 
and homeostasis, regulating many cellular functions including growth, adhesion, migration, 
apoptosis, and differentiation (Wu and Hill 2009). During early stages of tumor development, 
TGF-β has been shown to act as a tumor suppressor, inducing apoptosis in normal epithelial 
cells. However, in later stages of tumor development, TGF-β aids in tumor progression, by 
enhancing migration, invasion, survival, and EMT. This switch was found to be partially 
regulated by matrix rigidity, with decreased rigidity leading to apoptosis, and increased rigidity 
leading to EMT (Leight et al. 2012). 
Extensive research has focused on the signaling pathways of TGF-β, and how they 
regulate EMT. There are three isoforms of TGF-β, named TGF-β1, TGF-β2, and TGF-β3. They 
function by binding type I, type II, and type III receptors (TβRI, TβRII and TβRIII). Binding of 
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TGF-β to TβRII recruits and phosphorylates TβRI (Lei et al. 2002). Activated TβRI then 
phosphorylate Smad2 and Smad3 proteins, two of which then combine with Smad4 and 
translocate into the nucleus, where the complex can regulate gene expression.  Some of the 
transcriptional targets of TGF-β signaling include Snail/Slug, ZEB1/2 and Twist, all of which 
regulate EMT. TGF-β signaling also activates other pathways, including PI3K/Akt, Erk, and 
Rho-GTPases. The PI3K/Akt/mTOR pathway promotes increased protein synthesis, motility, 
and cell invasion (Katsuno, Lamouille, and Derynck 2013). The protein kinase mTOR complex 2 
directs the cytoskeletal reorganization during EMT. Small GTPases control cytoskeletal 
regulation as well, and are controlled by TGF-β signaling by transcriptional methods as well as 
post-transcriptional regulation. This signaling leads to proteasomal degradation, resulting in 
decreased stiffness and remodeling of the cytoskeletal response to enhance invasion (Moustakas 
and Heldin 2016). A summary of TGF-β signaling pathways can be found in Figure 2-4. 
 
Figure 2-4: Transforming Growth Factor Beta Regulation of Epithelial-Mesenchymal Transition. a) 
Epithelial-mesenchymal transition occurs when epithelial cells lose their cell-cell adhesions and apical-basal 
polarity, and gain properties of mesenchymal cells including enhanced mobility and invasion, characterized by the 
reorganization of the actin cytoskeleton, increased expression of matrix metalloproteinases (MMPs) and 
extracellular matrix proteins. b) TGF-β induces EMT through both the Smad pathway and non-Smad pathways. The 
Smad2/3 and Smad 4 complex translocates into the nucleus and regulates the transcription of target genes. Smad 
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signaling increases the expression of Snail/Slug, Zeb1/2 and Twist, which are responsible for repressing epithelial 
markers and activating mesenchymal markers. The PI3K-Akt-mTOR pathway and GTPases are also activated, 
increasing motility and invasion and changing actin organization (Katsuno, Lamouille, and Derynck 2013). 
TGF-β was found to be critical for the growth and survival of MDA-MB-231 cells. Upon 
sequestering active TGF-β1 and TGF-β2 using the expression of a soluble TGF-β type III 
receptor, sRIII, Smad2 phosphorylation was found to be decreased compared to the control cells, 
and it was further found that sRIII expression antagonized autocrine TGF-β activity. 
Additionally, when control MDA-MB-231 cells were treated with a recombinant sRIII or 
neutralizing antibody specific to TGF-β1 or TGF-β2, their growth was inhibited. A neutralizing 
antibody binds directly to the TGF-β protein, preventing it from activating the signaling 
pathway. When comparing cell death, it was found that sRIII clones had significantly more 
apoptosis than control cells (Lei et al. 2002). Similarly, another study inhibited TGF-β using both 
a neutralizing antibody (1D11) and a chemical inhibitor of the type I and type II receptors 
(LY2109761) in MDA-MB-231 cells. It was found that blocking TGF-β inhibited the 
phosphorylation of Smads 2 and 3. In vivo, treatment with the inhibitors reduced the burden of 
metastases, indicating the importance of TGF-β for the growth and metastasis of MDA-MB-231 
cells (Ganapathy et al. 2010; Liu et al. 2012).  
Blocking TGF-β was also found to alter the vasculature of tumors and improve the 
perfusion of vessels within the tumor, allowing for the distribution of drugs into the tumors. The 
extracellular matrix around the tumor was altered as well, with significantly decreased collagen I 
content, resulting in a less dense matrix that allowed better penetration of drug into the tumor 
tissues (Liu et al. 2012). These results indicate how targeting TGF-β may help lead to better 
patient outcomes by enhancing the susceptibility of tumors to traditional treatment methods. 
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2.4 The 3D Microenvironment and Tumor Behavior 
Factors related to the 3D environment of tumor cells, including the components of the 
extracellular matrix (ECM) and mechanical stiffness of the surrounding tissue, are important 
regulators of tumor progression. Part of the process of metastasis involves the ability of the 
cancer cells to degrade the basement membrane and ECM to migrate and spread to other tissues. 
Matrix metalloproteinases (MMPs) are enzymes that degrade components of the ECM, including 
collagen and fibronectin. Under normal conditions, MMPs and their specific tissue inhibitors of 
MMPs (TIMPs) have a tightly controlled balance that maintains the homeostasis of ECM 
degradation. High levels of certain MMPs have previously been shown to predict poor prognosis 
in cancer (Têtu et al. 2006). In breast cancer, MMP-2 and MMP-9, the gelatinases, are implicated 
for their specific degradation of collagen type IV, which is an abundant basement membrane 
protein in that tissue. MMP-14 is also implicated in breast cancer progression, since it is 
involved in MMP-2 activation and is important for invasion and migration (Gomes et al. 2012; 
Têtu et al. 2006). MMP-14 is a membrane bound MMP which localizes to structures called 
invadopodia in the membrane structure. Its direct degradation of the matrix enables it to promote 
cell invasion (Itoh 2015). In a study looking at the downregulation of MMP-14 in 231 cells, it 
was found that the growth of the primary tumor was not affected, however, the number of 
metastases to the lungs was significantly reduced (Perentes et al. 2011). This indicates the 
important role of MMP-14 in the metastasis of cancer cells. 
In a clinical study on the correlation between tissue stiffness and breast cancer prognosis, 
it was found that higher histologic grade was associated with higher mean stiffness (Evans et al. 
2012). Tumor stroma is characterized by remodeling and stiffening of the ECM, and the stiffness 
enhances the cell growth, survival, and migration of cancer cells. A study in rats found an 
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incremental stiffening of the mammary gland as it transitioned from normal, to premalignant, to 
invasive cancer, along with the adjacent stromal tissue becoming stiffer than normal as well. The 
increase in stiffness was associated with increased collagen crosslinking (Levental et al. 2009). 
In a study in mice, normal mammary tissue was found to have a stiffness of ~0.2 kPa, while 
tumor samples ranged from ~3-5 kPa, illustrating the dramatic changes in elastic modulus after 
tumor formation (Paszek et al. 2005). 
Since cancer cells are in a 3D rather than 2D environment in vivo, studying factors such 
as mechanical environment and ECM composition is best done either in an in vitro 3D model or 
an in vivo animal model. 3D in vitro models offer a useful alternative to the complexity of whole 
organism animal models, and offer the ability to tune the characteristics of the environment the 
cells are tested in. There are numerous approaches to 3D culture, including natural scaffolds, 
synthetic scaffolds, and cell excreted ECM (Nyga, Cheema, and Loizidou 2011). Synthetic 
hydrogels can be engineered to have specific mechanical and chemical properties to mimic 
certain properties of the native ECM. Using these approaches allows for the study of the effects 
of both the mechanical environment combined with other factors that may contribute to the 
behavior of cells, such as ECM components present or soluble factors.   
Chapter 3 Methodology 
3.1 Cell Culture 
MDA-MB-231 breast cancer cells with a stable lenti-viral knockdown of MYOF (MDA-
MB-231 MYOF KD) and lenti-viral control cells (MDA-MB-231 LTV CNTL) received from the 
Kniss lab were cultured in high glucose Dulbecco’s modified eagle medium (HG DMEM) 
supplemented with 10% fetal bovine serum (FBS) (VWR), 1% L-glutamine (Life Tech) and 1% 
penicillin-streptomyosin (Life Tech) for normal growth (Li et al. 2012). For experiments, cells 
were cultured in high glucose DMEM supplemented with 1% L-glutamine (Life Tech) and 1% 
pen-strep (Life Tech).  Insulin-Transferrin-Selenium-G (ITS) supplement (Invitrogen) was added 
for Western Blot, proliferation and metabolism studies. For migration assays, 10% charcoal 
stripped FBS was added to the experimental media. 
3.2 TGF-β1 Treatment 
Recombinant Human TGF-β1 (PeproTech) was used at a concentration of 2 ng/mL, and 
dissolved in 4 mM HCL with 0.1% bovine serum albumin (BSA) (Sigma-Aldrich). Cells were 
plated in growth medium and after 24 hours, were switched to experimental media supplemented 
with either TGF-β1 or vehicle control and cultured for 48 hours. 
3.3 ELISA 
Cells were plated at a density of 2.0x104 cells/cm2 with normal growth media in six-well 
culture plates and switched to experimental media after 24 hours. Cell culture supernatant was 
collected after 48 hours of culture in experimental media. Samples were assayed directly after 
collection. A Human TGF-β1 Quantikine ELISA kit (R&D Systems) was used to quantify the 
amount of TGF-β1 made by each cell type. The kit was used according to the manufacturer’s 
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protocol, and samples were activated prior to running the assay using a sample activation kit 
(R&D Systems). Absorbance values were measured at 450 nm and 540 nm with the Spectra Max 
M2 plate reader (Molecular Devices).  
3.4 Quantitative RT-PCR 
Cells were plated at a density of 1x107 cells/cm2 overnight (16 hrs) then starved for 2 
hours in serum-free media. Cells were then treated with TGF-β1 or vehicle control for 2 hours 
prior to lysis. RNA isolation was performed using the RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s protocol, using the Qiashredder columns (Qiagen) to homogenize the 
samples. The RNA was converted to complementary DNA using iScript (Bio-Rad) in a 20 µL 
reaction performed using a thermal cycler (BioRad) with 1 μg of RNA. The mRNA expression 
was analyzed using qRT-PCR in triplicate with SYBR Green reagent (Fisher Scientific) at 1:2 in 
each well, with cDNA at 1:100. The mRNA fold changes were determined using the ΔΔCT 
method normalized to the 18S endogenous control. The primer sequences are listed in Table 3-1.  
Table 3-1: Primer Sequences. Sequences used for quantitative RT-PCR. 
Primer Forward Sequence Reverse Sequence 
TGF-β1 (Yin et al. 
2016) 
GGCGATACCTCAGCAACCG AAGGCGAAAGCCCTCAAT 
Slug (Dhasarathy, 
Kajita, and Wade 
2007) 
AGATGCATATTCGGACCCAC CCTCATGTTTGTGCAGGAGA 
Snail (Medici, Hay, 
and Olsen 2008) 
ACCACTATGCCGCGCTCTT GGTCGTAGGGCTGCTGGAA 
Twist1 (Elias et al. 
2005) 
GAGTCCGCAGTCTTACGAGG CTGCCCGTCTGGGAATCACT 
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3.5 Western Blot 
Cells at a density of 2x104 cells/cm2 were plated in six-well culture dishes with growth 
media for 24 hours and then switched to experimental media with TGF-β1 or vehicle control. 
After 48 hours, plates were rinsed in ice-cold PBS and lysed for 10 minutes on ice using 
radioimmunoprecipitation assay (RIPA) buffer (Life Tech) with Halt protease and phosphatase 
inhibitor cocktails (Fisher Sci) at 1:100. Samples were centrifuged at 12,000 rpm for 15 minutes 
after lysis, and the supernatant was transferred to fresh pre-chilled tubes. Protein concentrations 
were determined using a μBCA protein assay (Thermo Fisher).  Equal amounts of protein (30 
μg) were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) with a 12% Bis-Tris Plus Gel (Invitrogen) and transferred to a polyvinylidene difluoride 
(PVDF) membrane (Fisher Sci). The membrane was blocked with Tris-buffered saline with 
Tween20 (TBST) (5% BSA (Sigma Aldrich) in TBS + 0.05% Tween20 (Sigma Aldrich)) for 1 
hour at room temperature. Membranes were probed with primary antibodies: mouse monoclonal 
E-cadherin (Cell Signaling Technologies), mouse monoclonal vimentin (Fisher Scientific), and 
the loading control mouse monoclonal glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(Fisher Scientific), diluted in blocking solution. After rinsing, membrane sections were incubated 
with horseradish peroxidase-conjugated secondary antibodies (Thermo Fisher) for 1 hour at 
room temperature and rinsed again 3 times. SuperSignal West femto (for E-cadherin) and pico 
(for vimentin and GAPDH) chemiluminescent substrates (Thermo Fisher) were added to the 
appropriate membrane sections for 5 minutes prior to imaging. Membranes were visualized using 
the LiCor Odyssey Fc Imaging System, then quantified using ImageJ (NIH, Imagej). 
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3.6 Cell Proliferation and Metabolism 
For proliferation studies, cells at a density of 2x104 cells/cm2 were plated in six-well 
culture dishes, and following 48 hours of culture in experimental media supplemented with either 
TGF-β1 or vehicle control, plates were rinsed with PBS and frozen at -70°C for at least 24 hours 
prior to assay. The CyQUANT Cell Proliferation assay kit (Invitrogen) was used according to the 
manufacturer’s protocol to determine the relative cell number. To determine cell metabolism, 
AlamarBlue cell viability reagent (Life Technologies) was added to each well at a 1:10 dilution 
for six hours prior to the 48 hour time point, then read using the Synergy HT plate reader 
(BioTek) at 540 nm excitation/590 nm emission. 
3.7 Migration 
Migration studies were performed using Ibidi® chambers and live cell tracking of cell 
movement. Cells were seeded at 2x104 cells per chamber, grown overnight in normal culture 
media, and then the cells were pretreated with or without TGF-β1 for 48 hours. After 48 hours, 
the Ibidi insert was removed, cells were washed to remove any non-adhered cells and 
experimental media was added to fill the well. An inverted fluorescence microscope (Olympus 
IX81) with live cell imaging chamber (Okolab) was used to record bright field images of cells 
every ten minutes over 24 hours. Time-lapse images thus collected were analyzed using image 
processing software ImageJ (NIH, Imagej) to track individual cell migration. Cell position data 
were then analyzed using MATLAB to determine cell migration parameters including 
accumulated distance, cell velocity, Euclidean distance and cell directionality. The code used for 
this analysis can be found in Appendix A.  
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3.8 Polyethylene Glycol (PEG) Hydrogels 
A master mix of the components of the hydrogel was made with 3 mM (6 wt%) 
polyethylene glycol-norbornene (PEG-NB), MMP crosslinker (KCGPQGIWGQCK), 1 mM 
CRGDS, 2 mM photoinitiator LAP, and 0.25 mM fluorogenic peptide (Leight et al. 2013). The 
fluorogenic peptide contains a quencher and a fluorophore, and after cleavage is able to fluoresce 
for detection. The peptide used in this study is sensitive to cleavage by MMP 14. In order to alter 
the stiffness of the hydrogel, different PEG-NB types and crosslinking ratios were used, as 
outlined in Table 3-2. Cells were encapsulated by making a concentrated cell suspension in 
phosphate buffered saline (PBS) which was added to the master mix, for a final cell density of 
4x106 cells/mL. Fifty µL of the master mix and cell solution was pipetted into a rubber gasket 
with a 6 mm inner diameter on a thiolated coverslip, to covalently link the gel to the coverslip. 
The solutions were then exposed to 365 nm light for 3 min to crosslink the gel. After 
encapsulation, gels were incubated in 1% charcoal stripped serum HG DMEM for 24 hours, and 
a 0 hour fluorescence reading was taken as a background. Six hours prior to the end of the 
experiment, AlamarBlue cell viability reagent (Life Technologies) was added to each well at a 
1:10 dilution. One hour prior to the final fluorescence reading, nucleic acid stain Hoechst 
(Invitrogen) was added to each well at a 1:2000 dilution. Fluorescence measurements were taken 
on the Spectra Max M2 plate reader (Molecular Devices) at 494 nm excitation (ex)/ 521 nm 
emission (em) for the fluorogenic peptide, 560 nm ex/ 590 nm em for AlamarBlue, and 350 nm 
ex/ 461 nm em for Hoechst.  Prior to the fluorescence reading for Hoescht, media were removed 
from the wells and PBS was added to remove any Hoescht that was not bound to the nuclear 
DNA. Fluorescence values were normalized both to cell metabolism (AlamarBlue) and DNA 
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content (Hoechst) to obtain the relative MMP activity. Coverslips were thiolated as described 
previously (Carman et al. 2006).  
Table 3-2: Experimental Setup of Gel Stiffness Experiments. Table of the PEG-NB used, along with the 
crosslinking ratio and corresponding Elastic Modulus for the gel stiffness experiments. 
PEG-NB Crosslinking Ratio Elastic Modulus 
(kPa) 
4 ARM 20K 1.0 0.753 
8 ARM 40K 0.70 1.428 
8 ARM 40K 0.85 2.599 
8 ARM 40K 1.0 3.427 
8 ARM 20K 0.70 2.577 
8 ARM 20K 0.85 5.387 
8 ARM 20K 1.0 6.211 
 
3.9 Statistical Analysis 
Data analysis for graphical representation and statistical results was performed using 
Prism version 7 (GraphPad). Error bars represent the standard deviation of the samples. For data 
sets with 3 or more groups, statistical analysis was performed using a two-way ANOVA 
followed by a Tukey’s Multiple Comparison Test with an alpha level of 0.05. For data with two 
sets, an unpaired one-tailed t-test was conducted to determine significance, with an alpha level of 
0.05. For the gel stiffness experiments, statistical analysis was performed using linear regression, 
to determine if the slopes and intercepts of the two data sets were significantly different, with a 
confidence interval of 95%. 
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Chapter 4 Results 
4.1 Transforming Growth Factor-β1 Induced Epithelial-Mesenchymal Transition 
MYOF knockdown results in a change in phenotype and morphology of the MDA-MB-
231 cells from mesenchymal to epithelial (Li et al. 2012). It is not known, however, the 
mechanism leading to this change after MYOF depletion, or if the transition is reversible. In 
order to determine if the MYOF KD cells retained their ability to undergo EMT, they were 
treated with TGF-β1, since TGF-β1 is known to be a potent stimulus of EMT. After treatment 
with exogenous TGF-β1 for 48 hours, MYOF KD cells had a dramatic change in morphology, as 
visualized using light microscopy. Vehicle-treated MYOF KD cells exhibit the cobblestone-like 
morphology characteristic of epithelial cells, and vehicle-treated control cells have the elongated, 
spindly shape characteristic of mesenchymal cells. The MYOF KD cells treated with TGF-β1 
appear more similar to the control cells, with a more elongated morphology, as seen in Figure 4-
1. Additionally, treatment with TGF-β1 was not found to significantly alter the proliferation or 
metabolism of the cells (data in Appendix B). 
 
Figure 4-1: Effect of TGF-β1 on Myoferlin Depleted MDA-MB-231 Cells. Phase images of MDA-MB-231 
MYOF KD cell morphology after treatment with TGF-β1.  
 
In addition to changes in morphology, an EMT is also accompanied by changes in protein 
expression of epithelial and mesenchymal markers. Western blot for common markers of EMT 
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was performed and results are shown in Figure 4-2. Vimentin, a common marker of a 
mesenchymal phenotype, was found to be significantly upregulated in the MYOF KD cells, and 
closer to the levels of vimentin in the control cells. Similarly, E-cadherin, a cell adhesion protein 
and marker of an epithelial phenotype, was found to be significantly decreased in the MYOF KD 
cells. Control cells treated with TGF-β1 showed little change. The morphology change together 
with the phenotypic change shown by western blot indicates that the MYOF KD cells underwent 
an EMT after being treated with TGF-β1, and therefore retain their plasticity. 
 
Figure 4-2: Western Blot of EMT Markers. A) Representative immunoblot of EMT markers vimentin and E-
cadherin in MDA-MB-231 control (CNTL) and myoferlin knockdown (KD) after treatment with vehicle control or 
TGF-β1 for 48 hours. B) E-cadherin expression levels normalized to the loading control GAPDH. C) Vimentin 
expression levels normalized to the loading control GAPDH. n=3+SD, *p<0.05, **p<0.01, ***p<0.001 
 
Further analysis of EMT was performed by determining the mRNA expression levels of 
transcription factors known to regulate EMT, Snail, Slug, and Twist, which repress E-cadherin. 
Both Snail and Slug were found to be significantly increased in MYOF KD cells upon treatment 
with TGF-β1, indicating that the MYOF KD cells were undergoing EMT as shown in Figure 4-3. 
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This result further supports the western blot data that an EMT has occurred in the MYOF KD 
cells, indicating that these cells are still capable of undergoing EMT after myoferlin depletion. 
Although average values of the vehicle control MYOF KD expression were lower than that of 
the control cells, this difference was not found to be significant. Furthermore, since Snail and 
Slug are both activated by TGF-β, an increase in expression following treatment in the control 
cells would be expected. Twist had high CT values, which prevented quantification, indicating 
that the MDA-MB-231 cells are expressing very low levels. 
 
Figure 4-3: mRNA Expression of Snail and Slug Transcription Factors. Snail and Slug mRNA were 
significantly increased in the MYOF KD cells after treatment with TGF-β1. n=3+SD, *p<0.05, **p<0.01, 
***p<0.001. 
 
4.2 Effect of Myoferlin Depletion on Transforming Growth Factor-β1 Production 
TGF-β1 is known to be an important regulator of EMT, due to its regulation of various 
transcriptional factors that influence the production of epithelial and mesenchymal markers. 
Additionally, it has previously been shown that MDA-MB-231 cells produce autocrine TGF-β1 
(Lei et al. 2002). Since the addition of TGF-β1 induced an EMT in the MYOF KD cells, we 
hypothesized that the depletion of MYOF may result in a reduction in autocrine TGF-β1 
production. In order to directly detect TGF-β1 levels made by the CNTL and MYOF KD cells, 
an ELISA was performed on the conditioned media of each cell type. The relative expression 
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levels were determined, and the MYOF KD cells were found to secrete approximately 20% less 
TGF-β1 than the control cells, with an average value of 0.77 +/- 0.052 when normalized to the 
control cells, as shown in Figure 4-4. The values were found to be statistically different, with a p-
value of 0.024 using an unpaired one-tailed t-test. Therefore, the MYOF KD expression of TGF-
β1 is significantly lower than that of the control cells. 
 
Figure 4-4: Relative TGF-β1 Concentration. An ELISA specific for TGF-β1 was used to quantify the relative 
concentration produced by the control and myoferlin depleted cells. n=3, *p<0.05. 
 
MYOF could regulate the protein expression of TGF-β1 through a variety of pathways, 
such as secretion from the cell or transcriptionally. To investigate the latter, measurement of 
TGF-β1 mRNA expression was determined using quantitative RT-PCR. Similar to the ELISA 
results, TGF-β1 expression was found to be decreased by approximately 30% in the MYOF KD 
cells, with an average value of 0.71 +/- 0.108 when normalized to the control cells, as seen in 
Figure 4-5. However, the data sets were not found to have a statistical difference, with a p-value 
of 0.0558 using an unpaired one-tailed t-test. Although these reductions in production are small, 
it is possible there is a critical level of TGF-β1 needed for EMT to occur. It has been shown 
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previously that MDA-MB-231s produce TGF-β and that autocrine signaling is required for cell 
survival (Lei et al. 2002). 
 
Figure 4-5: TGF-β1 mRNA Expression. Relative quantities of TGF-β1 mRNA were determined using quantitative 
RT-PCR. n=3, p=0.0558 
 
4.3 Effect of Transforming Growth Factor β on Migration 
MYOF depletion in MDA-MB-231s causes changes in cell migration. A previous study 
found MYOF KD cells to exhibit collective migration, rather than the single cell, random 
migration of the control cells, with decreased velocity and distance traveled, and increased 
directionality (Volakis et al. 2014). To determine if TGF-β1 treatment of the MYOF KD cells 
also affected cell migration, control and MYOF KD cells with or without TGF-β treatment were 
allowed to migrate for 24 hours and phase images were taken every ten minutes. The cells were 
first pretreated with or without TGF-β for 48 hours, to ensure the cells exhibited the EMT 
changes described above prior to the experiment. These images were then processed to analyze 
trends in migration patterns, the graphs of which are seen in Figure 4-6. Representative images 
of each condition before and after migration can also be seen in Figure 4-7.  
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Accumulated distance describes the total distance traveled by a cell, while Euclidean 
distance is the distance from the start point to the end point with a straight path between the 
points. Velocity is found from the distance traveled at each time point divided by the time 
between data points. Directionality indicates if the cell is preferentially moving in a certain 
direction, and is calculated by the Euclidean distance/accumulated distance. The trends in 
migration patterns follow the results seen previously, however most are not significant. After 
adding TGF-β1, there is a change in directionality, which is significantly decreased in the TGF-
β1 treated MYOF KD cells, to a value similar to that of the control cells. This indicates a change 
from the collective migration of the knockdown cells, to a single cell migration. The MYOF KD 
cells likely exhibit increased directionality and collective migration due to their increase in cell-
cell adhesion, inhibiting their ability to migrate away from their neighbors. A switch back to 
decreased directionality after TGF-β1 treatment further confirms the occurrence of EMT, since 
the cells are able to more easily break away from their neighbors to migrate as a single cell. The 
representative images seen in Figure 4-7 further support the result that the TGF-β1 treated 
MYOF KD cells exhibit single cell migration, since many cells are seen migrating away from 
their neighbors. The vehicle-treated MYOF KD cells appear as a single wall of cells, moving 
together. 
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Figure 4-6: Migration of MDA-MB-231 Cells. Graphs of accumulated distance, Euclidean distance, velocity, and 
directionality from 24 hours of migration, presented here is the average values across all cells of each condition. The 
MYOF KD cells were found to have significantly greater directionality than both the CNTL and MYOF KD with 
TGF-β1. n=3+SD, *p<0.05 
 
Figure 4-7: Phase Images Before and After Migration. Representative phase images of each condition before and 
after migration, showing the differences in the edge of the cells with each condition. 
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4.4 The Mechanical Environment and Matrix Metalloproteinase Activity of MDA-MB-231 Cells 
Since EMT is associated with increased MMP activity, and as cancer progresses, the 
surrounding tissue stiffens, we sought to examine the relationship between MMP activity and 
mechanical environment, and how myoferlin depletion affects their interaction (Levental et al. 
2009). To examine the effect of mechanical forces on the MMP activity of MDA-MB-231 
control and MYOF KD cells, cells were encapsulated in PEG hydrogels of varying elastic 
modulus. Stiffness was varied by changing the molecular weight and number of arms of the PEG 
and varying the crosslinking ratio, as described above. MMP activity was measured using a 
fluorescent peptide sensitive to cleavage by MMP-14, and normalizing to the metabolic activity 
and DNA content. MMP activity was found to increase with increasing elastic modulus of the gel 
for both the control and MYOF KD cells, as shown in Figure 4-8. Using linear regression 
analysis, the control and MYOF KD cells were found to have the same slope, indicating they 
have the same response to stiffness. However, the y-intercepts of each regression were found to 
be significantly different, with a p-value of 0.0055. Thus, the control cells have higher MMP 
activity than the MYOF KD cells across conditions.  
 
Figure 4-8: Effect of Gel Stiffness on MMP Activity of MDA-MB-231 Cells. Relationship between elastic 
modulus and MMP activity in the control and MYOF KD cells.   
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Chapter 5 Conclusions and Future Directions 
5.1 Conclusions 
EMT contributes to cancer progression and poor prognosis through either enhanced 
migration to form metastases or resistance to therapeutics. How EMT is regulated and ways to 
target this process is an area of importance in research, in order to develop new therapeutics and 
better understand the mechanism of disease. In this study, we have investigated the mechanism 
by which myoferlin depletion leads to the reversal of EMT, and whether this change is 
permanent. 
In Chapter 4.1, we demonstrated that the MDA-MB-231 MYOF KD cells retain their 
ability to undergo EMT. Treatment with exogenous TGF-β1 led to a visible morphology change 
in the MYOF KD cells to a spindle-like shape characteristic of mesenchymal cells, which was 
accompanied by a phenotypic change with an increase in vimentin and decrease in E-cadherin 
expression.  Thus, the mechanism of EMT remains intact in the MYOF KD cells. 
The production of autocrine TGF-β1 by each cell type was explored in Chapter 4.2. 
Direct detection of TGF-β1 showed approximately a 20% decrease in production by the MYOF 
KD cells relative to the control cells. Similarly, mRNA expression of TGF-β1 showed a 30% 
decrease in the MYOF KD cells relative to the control, although this change was not found to be 
significant. These results indicate that TGF-β1 production could be responsible in part for the 
MET occurring after MYOF depletion.  
Cell behavior including migration and MMP activity were investigated in Chapters 4.3 
and 4.4. Migration studies found TGF-β1 treated MYOF KD cells to have decreased 
directionality to levels similar to that of the control cells, indicating a change to single cell 
migration. Elastic modulus of the 3D environment was shown to have a significant effect on the 
28 
 
MMP activity of both the control and MYOF KD cells, with increasing stiffness resulting in 
corresponding increasing MMP activity. MYOF KD cells were found to have significantly lower 
MMP activity than the control cells, reinforcing their phenotype change, since EMT is associated 
with increased MMP activity.  
5.2 Future Directions 
In this study, we have demonstrated that the MYOF KD cells are capable of undergoing a 
phenotypical change to become more mesenchymal, however, corresponding studies on changes 
in cell behavior are lacking. Ongoing studies to examine the invasion of the MYOF KD cells 
after TGF-β1 treatment are being conducted, and would strengthen the conclusion that the cells 
have undergone EMT by showing behavior characteristic of mesenchymal cells, and similar to 
the control cells. Studies on the effect of mechanical environment with the hydrogels could be 
expanded to examine the effects of TGF-β1 treatment on the MYOF KD MMP activity after 
EMT is observed, to determine if MMP activity increases to values similar to the control cells.  
 Since we have shown that TGF-β1 production is affected by MYOF depletion, blocking 
TGF-β in the control cells and observing MET would strengthen this connection. Ongoing 
studies in the lab have begun to examine this possibility using both a neutralizing antibody and a 
pharmacological inhibitor (data not shown). Issues arose with cell viability during the 
experiments, likely due to the need of MDA-MB-231 cells to have autocrine TGF-β for their 
growth and survival (Lei et al. 2002). Future studies could examine a dose dependent response, 
to determine if there is a critical amount of inhibition that can cause MET without severely 
inhibiting cell growth. Along with inducing MET, studies on cell behavior with inhibitors could 
be conducted as well to show a change to a more epithelial phenotype and activity. Similarly, 
treatment with TGF-β1 could also be examined with a dose response, to determine the 
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concentration of TGF-β1 necessary for EMT to occur in the MYOF KD cells. The concentration 
of TGF-β1 used for treatment (2ng/mL) was much higher than the concentrations found to be 
made by MDA-MB-231s (approximately 100-200 pg/mL). 
Another possible direction would be to explore other proteins that myoferlin interacts 
with to potentially identify other mechanisms by which myoferlin depletion is leading to MET. 
One such protein recently discovered to be regulated by myoferlin is A Disintegrin and 
Metalloproteinase 12 (ADAM12), which is involved in cancer formation and progression by 
enhancing proliferation and invasion and is highly expressed in breast cancer. Myoferlin was 
found to enhance the stability and enzymatic activity of ADAM12, which would help lead to the 
reduction of its substrate, E-cadherin, a known EMT regulator (Zhou et al. 2016). ADAM12 has 
further been found to contribute to TGF-β induced EMT, further contributing to the possibility of 
its role in the present mechanism. However, inhibiting ADAM12 in MDA-MB-231 cells did not 
reverse their mesenchymal phenotype, indicating that ADAM12 alone is not inducing EMT 
(Ruff et al. 2015). Exploring the interaction of all three factors, myoferlin, TGF-β, and 
ADAM12, could be interesting and lead to new insight about the mechanism of myoferlin 
depletion in MDA-MB-231 cells. Furthermore, identifying other proteins that interact with 
myoferlin, either through literature review or bioinformatics analysis, could aid in the discovery 
of other potential targets that contribute to the MET seen with myoferlin depletion.  
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Appendix A: MATLAB Code 
clear all 
files=dir('*KD_Control*.xls'); 
cnt=1; 
for i=1:size(files) 
    A=dlmread(files(i).name,'\t',1,0); 
    cell_count=A(length(A),2); 
    for j=1:cell_count 
        B=A(A(:,2)==j,2:5); 
        for k=2:length(B) 
            Dist(k-1)=sqrt(((B(k,3)-B((k-1),3))*(1/1.55))^2+((B(k,4)-B((k-
1),4))*(1/1.55))^2); 
        end 
        Acc_dist(cnt)=sum(Dist); 
        Velocity(cnt)=mean(Dist)/10; 
        Euc_dist(cnt)=sqrt(((B(end,3)-B(1,3))*(1/1.55))^2+((B(end,4)-
B(1,4))*(1/1.55))^2); 
        Directionality(cnt)=Euc_dist(cnt)/Acc_dist(cnt); 
        cnt=cnt+1; 
    end 
end 
filename=sprintf('%s_Analysis.xls',files(1).name(end-19:end-4)); 
xlswrite(filename,[Acc_dist',Velocity',Euc_dist',Directionality']); 
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Appendix B: Cell Proliferation and Metabolism 
 
 
Figure B-1: Effect of TGF-β1 on Proliferation and Metabolism. A.) Cells were cultured +/- TGF-β1 for 48 
hours. Relative cell proliferation was determined using the CyQUANT kit according to the manufacturer’s 
instructions. Values were normalized to the control treated condition for each cell type. Statistical analysis using a 
two-way ANOVA with a Tukey’s multiple comparison test found no significant differences in the data set. n=3 B.) 
Cells were cultured +/- TGF-β1 for 48 hours. Cell metabolism was determined using the AlamarBlue cell viability 
reagent. Values were normalized to the control cells vehicle treatment. A two-way ANOVA with Tukey’s multiple 
comparison test was used to determine significance, and no significant differences were found within the data set. 
n=3 
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